The Stanford Medicine Department of Radiation Oncology is the first radiation oncology program in the world to test a new biology-guided radiation therapy platform known as RefleXionTM X1.
The RefleXionTM X1 machine received marketing clearance from the US food and Drug Administration (FDA) for stereotactic body radiotherapy (SRS) and intensity modulated radiotherapy (IMRT). Stanford Medicine Radiation Oncology has completed treatment of its first patient using this approved functionality.
The RefleXionTM X1 machine combines a 6MV linear accelerator, 16-slice onboard fan-beam CT, on board PET detector and a rotating ring gantry.
RefleXionTM X1 is the first device to combine radiotherapy with PET technology. When PET radio tracers are introduced into the body, cancer absorbs them and acts like a biological beacon. The biology guided radiotherapy (BgRT) technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency. This has the potential to increase the therapeutic ratio of high dose ablative radiotherapy delivered to primary or metastatic tumors.
Stanford Medicine currently is conducting a phase 1 clinical trial that begins to evaluate the performance and safety of BgRT. BgRT is not currently available for routine clinical use.
Lucas Vizthum, MD is a Clinical Assistant Professor of Radiation Oncology at Stanford University School of Medicine. He is leading the clinical trial with Daniel Chang, MD, professor Radiation Oncology.
Currently, the RefleXionTM X1 is cleared for the delivery of sterotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).